Our findings present the rationale for progression of a pan-lysyl oxidase inhibitor aimed at eliciting a reduction in stromal matrix to potentiate chemotherapy in pancreatic ductal adenocarcinoma. This evidence concerns the gene LOX and pancreatic ductal adenocarcinoma.